Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria.
Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari M, Migliore F, Pilichou K, Rampazzo A, Rigato I, Rizzo S, Thiene G, Anastasakis A, Asimaki A, Bucciarelli-Ducci C, Haugaa KH, Marchlinski FE, Mazzanti A, McKenna WJ, Pantazis A, Pelliccia A, Schmied C, Sharma S, Wichter T, Bauce B, Basso C.
Int J Cardiol. 2020 Nov 15;319:106-114. doi: 10.1016/j.ijcard.2020.06.005. Epub 2020 Jun 16.
Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.
Munkhaugen J, Kristensen AMD, Halvorsen S, Holmager T, Olsen MH, Bakken A, Sehested TSG, Ruddox V, Mæng M, Vikenes K, Jensen SE, Steigen T, Lambrechtsen J, Jortveit J, Bovin A, Schirmer H, Christiansen MK, Wiseth R, Mikkelsen D, Larsen AI, Lyngby Kjærgaard C, Andresen K, Gustafsson I, Tuseth V, Larsen ML, Deeg PS, Veien K, Bøhmer E, Bøtker HE, Brattrud AO, Brønnum-Schou J, Pettersen AR, Bang LE, Øie E, Engstrøm T, Borg EB, Kristensen K, Nymo SH, Gislason G, Vethe NT, Abdulla JAM, Dammen T, Mouridsen MR, Bendz B, Bertelsen MLN, Hove JD, Schierbeck L, Snoer M, Davidsen C, Egholm G, Thomsen KK, Jadou G, Poenaru M, Krarup NT, Böttcher M, Stæhr PB, Zwisler AD, Edvardsen T, Torp-Pedersen C, Otterstad JE, Lange T, Fagerland MW, Atar D, Prescott E; BETAMI–DANBLOCK Investigators.
N Engl J Med. 2025 Nov 13;393(19):1901-1911. doi: 10.1056/NEJMoa2505985. Epub 2025 Aug 30.
Efficacy of moricizine in malignant ventricular arrhythmias.
Horowitz LN.
Am J Cardiol. 1990 Feb 20;65(8):41D-46D; discussion 68D-71D. doi: 10.1016/0002-9149(90)91416-4.
[Malignant ventricular arrhythmias in patients with a right bundle-branch block and persistent ST segment elevation in V1-V3: a probable arrhythmogenic cardiomyopathy of the right ventricle].
Naccarella F.
G Ital Cardiol. 1993 Dec;23(12):1219-22.
The Role of Contrast-Enhanced Cardiac Magnetic Resonance in the Assessment of Patients with Malignant Ventricular Arrhythmias.
Banerji D, Mendoza D, Ghoshhajra BB, Hedgire SS.
Magn Reson Imaging Clin N Am. 2019 Aug;27(3):475-490. doi: 10.1016/j.mric.2019.04.011.
Patients with malignant or potentially malignant ventricular arrhythmias: opportunities and limitations of drug therapy in prevention of sudden death.
Bigger JT Jr.
J Am Coll Cardiol. 1985 Jun;5(6 Suppl):23B-26B. doi: 10.1016/s0735-1097(85)80521-0.
Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias.
Anderson JL.
Am J Cardiol. 1990 Jan 16;65(4):36B-42B. doi: 10.1016/0002-9149(90)91289-i.
Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy.
Escobar-Lopez L, Ochoa JP, Mirelis JG, Espinosa MÁ, Navarro M, Gallego-Delgado M, Barriales-Villa R, Robles-Mezcua A, Basurte-Elorz MT, Gutiérrez García-Moreno L, Climent V, Jiménez-Jaimez J, Mogollón-Jiménez MV, Lopez J, Peña-Peña ML, García-Álvarez A, Brion M, Ripoll-Vera T, Palomino-Doza J, Tirón C, Idiazabal U, Brögger MN, García-Hernández S, Restrepo-Córdoba MA, Gonzalez-Lopez E, Méndez I, Sabater M, Villacorta E, Larrañaga-Moreira JM, Abecia A, Fernández AI, García-Pinilla JM, Rodríguez-Palomares JF, Gimeno-Blanes JR, Bayes-Genis A, Lara-Pezzi E, Domínguez F, Garcia-Pavia P.
J Am Coll Cardiol. 2021 Oct 26;78(17):1682-1699. doi: 10.1016/j.jacc.2021.08.039.
Sudden cardiac death, ventricular arrhythmias and hypertensive left ventricular hypertrophy.
Dunn FG, Pringle SD.
J Hypertens. 1993 Oct;11(10):1003-10. doi: 10.1097/00004872-199310000-00002.
Electrocardiographic recognition of benign and malignant right ventricular arrhythmias.
Lee J, Adeola O, Garan H, Stevenson WG, Yarmohammadi H.
Europace. 2021 Sep 8;23(9):1338-1349. doi: 10.1093/europace/euab047.
